AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Fmr LLC

Fmr LLC increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,117,447 shares of the company’s stock after purchasing an additional 258,477 shares during the quarter. Fmr LLC owned 0.75% of AstraZeneca worth $1,801,080,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AZN. Bank of Montreal Can grew its position in AstraZeneca by 109.6% in the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after acquiring an additional 1,605,758 shares in the last quarter. Private Trust Co. NA grew its position in AstraZeneca by 12.1% in the third quarter. Private Trust Co. NA now owns 4,509 shares of the company’s stock valued at $351,000 after acquiring an additional 488 shares in the last quarter. Brown Brothers Harriman & Co. grew its position in AstraZeneca by 7.3% in the third quarter. Brown Brothers Harriman & Co. now owns 6,506 shares of the company’s stock valued at $507,000 after acquiring an additional 444 shares in the last quarter. DRW Securities LLC grew its position in AstraZeneca by 49.8% in the third quarter. DRW Securities LLC now owns 37,468 shares of the company’s stock valued at $2,919,000 after acquiring an additional 12,459 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd grew its position in AstraZeneca by 52.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 26,823 shares of the company’s stock valued at $2,090,000 after acquiring an additional 9,203 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on AZN shares. TD Cowen increased their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

AstraZeneca stock opened at $66.36 on Wednesday. The stock has a market cap of $205.76 billion, a P/E ratio of 31.75, a price-to-earnings-growth ratio of 1.22 and a beta of 0.47. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average of $72.94 and a 200-day moving average of $77.65. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the business posted $0.87 earnings per share. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, analysts expect that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.